BOTHELL, Wash., April 5 /PRNewswire-FirstCall/ -- Helix BioMedix, Inc.
(OTC: HXBM.OB), a developer of bioactive peptides, today announced that a
review article titled "Antimicrobial peptides: therapeutic potential" was
published in the April 2006 edition of Expert Opinion on Pharmacotherapy, a
unique source of peer-reviewed drug evaluations and reviews. The article
discusses initiatives underway to develop peptide-based therapeutics as
well as the wide range of clinical applications that companies are
pursuing. Authors of the review article were Helix BioMedix's Principal
Scientist Dr. Lijuan Zhang and Chief Scientific Officer Dr. Timothy J.
Falla.
"There are certain attributes of antimicrobial peptides, including
broad-spectrum cidal activity, novel mechanism of action and ease of
synthesis, that make them excellent candidates for development as
anti-infective therapeutics," commented Timothy J. Falla. "As the
fundamental issues of stability, toxicity and cost are addressed and a
wider range of clinical indications emerge, there has been a resurgence of
interest in peptide-based therapeutics, particularly in the areas of
infection, dermatology, cancer and inflammation. At Helix BioMedix, we are
currently in preclinical testing with a number of peptides targeted at
wound management and have also recently developed a series of hexapeptides
for dermatological indications. With the recent advancements being made, we
believe that the peptides of today have a much greater chance of achieving
clinical success."
The review article in the April 2006 edition of Expert Opinion on
Pharmacotherapy can be found on-line at article:
http://www.expertopin.com/doi/abs/10.1517/14656566.7.6.653 .
Expert Opinion on Pharmacotherapy is a unique source of peer-reviewed
drug evaluations and reviews and is internationally recognized as a leader
in competitor intelligence to the pharmaceutical industry. Published by
Informa Healthcare, it provides comprehensive coverage of the emerging
literature on and experience with newly approved compounds and an evaluated
assessment of the likely impact of these new agents on existing
pharmacotherapy of specific diseases. Expert Opinion on Pharmacotherapy
focuses on new drugs and drug classes from development Phase III to those
that have been available to pharmacopoeia for up to 5 years.
About Helix BioMedix
Helix BioMedix, Inc. is a biopharmaceutical company that has a
portfolio of issued patents that covers six distinct classes of peptides,
including over 100,000 unique peptide sequences. The company's mission is
to become the industry leader in developing and commercializing small
proteins known as bioactive peptides. The antimicrobial and wound healing
properties of these peptides qualify them for inclusion in a wide range of
both pharmaceutical and consumer products. The company is currently focused
on the development of selected peptides as topical anti-infectives and in
wound healing applications. Non-pharmaceutical applications being pursued
by Helix BioMedix include adjuvants for cosmetics/cosmeceuticals, personal
care, plant health, animal health and wide-spectrum biocides. More
information about the company and its proprietary peptides can be found on
the company's website at http://www.helixbiomedix.com.
Important Notice
This press release contains forward-looking statements (statements
which are not historical facts) within the meaning of the Private
Securities Litigation Reform Act of 1995. These forward-looking statements
include statements regarding activities, events or developments that the
company expects, believes or anticipates may occur in the future, including
statements related to our potential growth, product development and
commercialization and revenue. A number of factors could cause actual
results to differ from those indicated in the forward-looking statements,
including the company's ability to successfully raise additional capital,
enter into revenue generating license agreements, continue its research and
development efforts, including pre-clinical and clinical studies, and
general economic conditions. Additional assumptions, risks and
uncertainties are described in detail in our reports and other filings with
the Securities and Exchange Commission. Such filings are available on our
website or at http://www.sec.gov. Readers are cautioned that such forward-looking
statements are not guarantees of future performance and that actual results
or developments may differ materially from those set forth in the
forward-looking statements. The company undertakes no obligation to
publicly update or revise forward-looking statements to reflect subsequent
events or circumstances.
Contact:
Helix BioMedix, Inc.
David H. Kirske, 425-402-8400
dkirske@helixbiomedix.com
or:
Investor Relations:
Cameron Associates
Alison Ziegler, 212-554-5469
alison@cameronassoc.com
SOURCE Helix BioMedix, Inc.
 back to top
Related links:
http://www.helixbiomedix.com
CONTACT:
David H. Kirske of Helix BioMedix, Inc.,
+1-425-402-8400, or dkirske@helixbiomedix.com; or investors,
Alison Ziegler of Cameron Associates, +1-212-554-5469, or
alison@cameronassoc.com, for Helix BioMedix, Inc.
|
